Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)-Reference-Cited by-同舟云学术

Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

Published:2024-08 Issue:7 Volume:47 Page:750-758
ISSN:2444-3824
Container-title:Gastroenterología y Hepatología (English Edition)
language:en
Short-container-title:Gastroenterología y Hepatología (English Edition)

Author:

Casas Deza Diego,Julián Gomara Ana Belén,Caudevilla Biota Eva,Beltrán Belén,Domènech Eugeni,Gutiérrez Casbas Ana,Mañosa Miriam,Zabana Yamile,Roc Alfaro Lourdes,Valverde Romero Emilio,García González Elena,Sicilia Beatriz,Laredo Viviana,Alcalá Escriche Maria José,Madero Velázquez Lucia,Ferreiro-Iglesias Rocío,Palmero Pérez Antonia,Calafat Margalida,Rubio Iturria Saioa,Moraleja Yudego Irene,Ber Nieto Yolanda,García Mateo Sandra,Gisbert Javier P.,Vicente Lidón Raquel,Arias Lara,Alfambra Erika,Doñate Borao Ana Belén,Peña González Elena,Corsino Roche Pilar,Vicuña Arregui Miren,Elorza Ainara,Domínguez Cajal Manuel,Chaparro María,Barreiro-de Acosta Manuel,García-López Santiago

Publisher

Elsevier BV

Reference27 articles.

1. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis;Zeng;BMC Med,2022

2. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease;Gisbert;Am J Gastroenterol,2012

3. Updates on vaccinating the inflammatory bowel disease patient;Zullow;Expert Rev Gastroenterol Hepatol,2019

4. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systemic review and meta-analysis;Sung;J Chin Med Assoc,2022

5. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD;Kennedy;Gut,2021